

~~A2 ³² 10.~~ A vesicle or droplet according to [any one of the preceding claims] claim 1 wherein the size of the vesicle or droplet is from 100 nm to 10 μ m.

~~A3 13.~~ A vesicle or droplet according to [any one of the preceding claims] claim 1 which further comprises a pharmaceutically active compound.

16. A process for preparing a vesicle as claimed in [any one of claims 1, 2 or 6 to 15] claim 1, which process comprises

- a) forming a vesicle in an aqueous mixture comprising a phospholipid, and
- b) calcifying the vesicle by contacting said vesicle with an aqueous solution comprising calcium and phosphate ions.

~~17.~~ A process for preparing a hydrophobic droplet as defined in [any one of claims 3 to 15] claim 1 which process comprises

- a) forming a ~~hydrophobic~~ droplet in an aqueous mixture comprising a hydrophobic liquid or solid and a surfactant, and
- b) calcifying the droplet by contacting said droplet with an aqueous solution comprising calcium and phosphate ions.

~~18.~~ A process according to claim [16 or claim] 17 wherein the aqueous mixture further comprises an alcohol.

20. A process according to claim 18 [or claim 19] wherein the concentration of alcohol is no more than 10% by volume of the aqueous mixture.

21. A process according to [any one of claims 16 to 20] claim 16 wherein the ratio of calcium to phosphate ions in the aqueous solution is from 1:1 to 2:1.

24. A vesicle according to claim 1 prepared by the process according to [any one of claims 16 or 18 to 23] claim 16.

25. A droplet according to claim 3 prepared by the process according to [any one of claims 17 to 23] claim 17.

26. A solid substrate wherein regions of said substrate have attached thereto a layer comprising vesicles or droplets as claimed in [any one of claims 1 to 15, 24 or 25] claim 1 with other region or regions having no vesicles or droplets attached thereto.

30. A process for preparing a substrate according to [any one of claims 26 to 29] claim 26 which process comprises electrolytically depositing the coating comprising vesicles or droplets onto the conducting regions of the substrate.

32. A substrate according to [any one of claims 26 to 29] claim 26 for use in the treatment of the human or animal body.

33. Use of a substrate according to [any one of claims 26 to 29] claim 26 in the manufacture of a medically acceptable implant the treatment of bone disorders or in the delivery of pharmaceutically active compounds.

Remarks

The above amendments are being made to eliminate multiple dependencies in the claims of this application.

No fee is believed necessary to enter this amendment. However if a fee is necessary, please charge Deposit Account 17-0055.